Biomea posts modest Phase 1 results for oral GLP-1 drug, shares slide

Biomea Fusion released Phase 1 data for its oral small‑molecule GLP‑1 agonist BMF‑650, positioning the program as a potential partner opportunity that could separate efficacy from gastrointestinal side effects.

The trial showed average weight loss of 1.5% to 3.2% after 29 days across four cohorts, while a fifth, confined cohort lost 6.1%. However, the two placebo participants in that group also lost weight, making the overall effect modest.

Company officials framed the limited weight loss as intentional, stating the goal was to avoid the strong gastrointestinal reactions seen with other GLP‑1 drugs rather than to achieve maximal weight reduction.

Investors responded negatively, driving the stock lower after the data release, reflecting doubts about the candidate’s competitive edge following recent FDA approval of a rival oral GLP‑1 therapy.